SOLID TUMOURS:@0.084848:0.038601:0.266058:0.038601:0.266058:0.019343:0.084848:0.019343:0.011712:0.020438:0.010866:0.005315:0.017498:0.006515:0.010019:0.015405:0.021613:0.020438:0.015405:0.014276:0.011712
72:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
REFERENCES:@0.084242:0.093226:0.195079:0.093226:0.195079:0.077192:0.084242:0.077192:0.011161:0.010006:0.009236:0.010006:0.011161:0.010006:0.014239:0.015009:0.010006:0.010006
1. :@0.084242:0.109956:0.103194:0.109956:0.103194:0.095950:0.084242:0.095950:0.009476:0.004738:0.004738
 Ravaud A,  Motzer  RJ,  Pandha  HS, :@0.120589:0.109956:0.424720:0.109956:0.424720:0.095950:0.120589:0.095950:0.000000:0.010382:0.011682:0.009476:0.011682:0.010399:0.011716:0.009219:0.012657:0.004738:0.004738:0.004464:0.015719:0.011203:0.005798:0.007269:0.011118:0.005148:0.004738:0.004456:0.010382:0.008244:0.004738:0.004738:0.004468:0.010126:0.011682:0.010434:0.011716:0.010434:0.011682:0.004738:0.004468:0.011682:0.008518:0.004738:0.004738
et  al:@0.429186:0.109956:0.470411:0.109956:0.470411:0.095950:0.429186:0.095950:0.011118:0.005798:0.004738:0.004468:0.011682:0.003421
. :@0.470411:0.109956:0.479887:0.109956:0.479887:0.095950:0.470411:0.095950:0.004738:0.004738
Adjuvant sunitinib in high-risk renal-cell car-:@0.120589:0.124067:0.475161:0.124067:0.475161:0.110061:0.120589:0.110061:0.012657:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.004829:0.006636:0.010399:0.010434:0.003421:0.005798:0.003421:0.010434:0.003421:0.011665:0.004841:0.003421:0.010434:0.004830:0.010434:0.003421:0.011511:0.010434:0.005679:0.005148:0.003421:0.006636:0.008586:0.004829:0.005078:0.011118:0.010434:0.011682:0.003421:0.005679:0.011067:0.011118:0.003421:0.003421:0.004841:0.011067:0.011682:0.005148:0.005679
cinoma after nephrectomy. :@0.120589:0.138178:0.357825:0.138178:0.357825:0.124172:0.120589:0.124172:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.005838:0.011682:0.005371:0.005798:0.011118:0.005148:0.005833:0.010434:0.011118:0.011665:0.010434:0.005073:0.011118:0.011067:0.005798:0.011203:0.016044:0.009168:0.004738:0.004738
N Engl J Med:@0.358921:0.138178:0.470421:0.138178:0.470421:0.124172:0.358921:0.124172:0.012657:0.005834:0.009168:0.010434:0.011511:0.003421:0.005839:0.008244:0.005838:0.015719:0.011118:0.011716
. :@0.470421:0.138178:0.479897:0.138178:0.479897:0.124172:0.470421:0.124172:0.004738:0.004738
2016; 375:2246-2254.:@0.120589:0.152289:0.287357:0.152289:0.287357:0.138284:0.120589:0.138284:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
2. :@0.084242:0.166400:0.103194:0.166400:0.103194:0.152395:0.084242:0.152395:0.009476:0.004738:0.004738
 Mickisch  GH,:@0.120589:0.166400:0.230202:0.166400:0.230202:0.152395:0.120589:0.152395:0.000000:0.015719:0.003421:0.011067:0.008586:0.003421:0.006636:0.011067:0.010434:0.004738:0.003190:0.014915:0.011682:0.004738
 et al.:@0.230202:0.166400:0.282798:0.166400:0.282798:0.152395:0.230202:0.152395:0.007919:0.011118:0.005798:0.007919:0.011682:0.003421:0.004738
 Radical  nephrectomy :@0.282798:0.166400:0.479882:0.166400:0.479882:0.152395:0.282798:0.152395:0.007919:0.010382:0.011682:0.011716:0.003421:0.011067:0.011682:0.003421:0.004738:0.003195:0.010434:0.011118:0.011665:0.010434:0.005073:0.011118:0.011067:0.005798:0.011203:0.016044:0.009168:0.004738
plus interferon-alfa-based immunotherapy :@0.120589:0.180511:0.479890:0.180511:0.479890:0.166506:0.120589:0.166506:0.011665:0.003421:0.010399:0.006636:0.006808:0.003421:0.010434:0.005798:0.011118:0.005963:0.005371:0.011118:0.005077:0.011203:0.010434:0.005679:0.011682:0.003421:0.005371:0.011682:0.005679:0.011665:0.011682:0.006636:0.011118:0.011716:0.006808:0.003421:0.016044:0.016044:0.010399:0.010434:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738
compared with interferon alfa  alone in :@0.120589:0.194622:0.479878:0.194622:0.479878:0.180617:0.120589:0.180617:0.011067:0.011203:0.016044:0.011665:0.011682:0.005078:0.011118:0.011716:0.011460:0.014214:0.003421:0.005798:0.010434:0.011460:0.003421:0.010434:0.005798:0.011118:0.005961:0.005371:0.011118:0.005075:0.011203:0.010434:0.011460:0.011682:0.003421:0.005371:0.011682:0.004738:0.006732:0.011682:0.003421:0.011203:0.010434:0.011118:0.011460:0.003421:0.010434:0.004738
metastatic renal-cell carcinoma: a ran-:@0.120589:0.208733:0.475161:0.208733:0.475161:0.194728:0.120589:0.194728:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.012024:0.005078:0.011118:0.010434:0.011682:0.003421:0.005679:0.011067:0.011118:0.003421:0.003421:0.012024:0.011067:0.011682:0.005029:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.004738:0.012024:0.011682:0.012024:0.005148:0.011682:0.010434:0.005679
domised trial. :@0.120589:0.222844:0.236129:0.222844:0.236129:0.208839:0.120589:0.208839:0.011716:0.011203:0.016044:0.003421:0.006636:0.011118:0.011716:0.004738:0.005798:0.005148:0.003421:0.011682:0.003421:0.004738:0.004738
Lancet.:@0.236129:0.222844:0.298868:0.222844:0.298868:0.208839:0.236129:0.208839:0.007902:0.011682:0.010434:0.011067:0.011118:0.005798:0.004738
 2001;358(9286):966.:@0.298851:0.222844:0.463087:0.222844:0.463087:0.208839:0.298851:0.208839:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.004738
3. :@0.084242:0.236956:0.103194:0.236956:0.103194:0.222950:0.084242:0.222950:0.009476:0.004738:0.004738
 Flanigan RC,:@0.120589:0.236956:0.226676:0.236956:0.226676:0.222950:0.120589:0.222950:0.000000:0.008296:0.003421:0.011682:0.010434:0.003421:0.011511:0.011682:0.010434:0.006180:0.010382:0.013906:0.004738
 et al.:@0.226676:0.236956:0.275782:0.236956:0.275782:0.222950:0.226676:0.222950:0.006175:0.011118:0.005798:0.006175:0.011682:0.003421:0.004738
 Nephrectomy followed :@0.275782:0.236956:0.479880:0.236956:0.479880:0.222950:0.275782:0.222950:0.006175:0.012657:0.011118:0.011665:0.010434:0.005071:0.011118:0.011067:0.005798:0.011203:0.016044:0.009168:0.006175:0.005371:0.011203:0.003421:0.003421:0.011203:0.014214:0.011118:0.011716:0.004738
by interferon alfa-2b compared with inter-:@0.120589:0.251067:0.475145:0.251067:0.475145:0.237061:0.120589:0.237061:0.011665:0.009168:0.005952:0.003421:0.010434:0.005798:0.011118:0.005959:0.005371:0.011118:0.005077:0.011203:0.010434:0.005952:0.011682:0.003421:0.005371:0.011682:0.005679:0.009476:0.011665:0.005969:0.011067:0.011203:0.016044:0.011665:0.011682:0.005077:0.011118:0.011716:0.005952:0.014214:0.003421:0.005798:0.010434:0.005952:0.003421:0.010434:0.005798:0.011118:0.005148:0.005679
feron alfa-2b alone for metastatic renal-cell :@0.120589:0.265178:0.479880:0.265178:0.479880:0.251172:0.120589:0.251172:0.005371:0.011118:0.005075:0.011203:0.010434:0.003459:0.011682:0.003421:0.005371:0.011682:0.005679:0.009476:0.011665:0.003472:0.011682:0.003421:0.011203:0.010434:0.011118:0.003462:0.005371:0.011203:0.005148:0.003457:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.003464:0.005078:0.011118:0.010434:0.011682:0.003421:0.005679:0.011067:0.011118:0.003421:0.003421:0.004738
cancer. :@0.120589:0.279289:0.189321:0.279289:0.189321:0.265284:0.120589:0.265284:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004738:0.004738
N Engl J Med:@0.189321:0.279289:0.297524:0.279289:0.297524:0.265284:0.189321:0.265284:0.012657:0.004738:0.009168:0.010434:0.011511:0.003421:0.004738:0.008244:0.004738:0.015719:0.011118:0.011716
. 2001;345(23):1655.:@0.297500:0.279289:0.456998:0.279289:0.456998:0.265284:0.297500:0.265284:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
4. :@0.084242:0.293400:0.103194:0.293400:0.103194:0.279395:0.084242:0.279395:0.009476:0.004738:0.004738
 Hudes G,:@0.120589:0.293400:0.195990:0.293400:0.195990:0.279395:0.120589:0.279395:0.000000:0.011682:0.010399:0.011716:0.011118:0.006636:0.004196:0.014915:0.004738
 et al.:@0.195990:0.293400:0.241129:0.293400:0.241129:0.279395:0.195990:0.279395:0.004191:0.011118:0.005798:0.004191:0.011682:0.003421:0.004738
 Temsirolimus, interferon alfa, :@0.241129:0.293400:0.479877:0.293400:0.479877:0.279395:0.241129:0.279395:0.004191:0.006447:0.011118:0.016044:0.006636:0.003421:0.005083:0.011203:0.003421:0.003421:0.016044:0.010399:0.006636:0.004738:0.004191:0.003421:0.010434:0.005798:0.011118:0.005959:0.005371:0.011118:0.005077:0.011203:0.010434:0.004191:0.011682:0.003421:0.005371:0.011682:0.004738:0.004738
or  both  for  advanced renal-cell carcino-:@0.120589:0.307511:0.475147:0.307511:0.475147:0.293506:0.120589:0.293506:0.011203:0.005148:0.004738:0.003753:0.011665:0.011203:0.005798:0.010434:0.004738:0.003753:0.005371:0.011203:0.005148:0.004738:0.003753:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.008501:0.005078:0.011118:0.010434:0.011682:0.003421:0.005679:0.011067:0.011118:0.003421:0.003421:0.008501:0.011067:0.011682:0.005029:0.011067:0.003421:0.010434:0.011203:0.005679
ma. :@0.120589:0.321622:0.157791:0.321622:0.157791:0.307617:0.120589:0.307617:0.016044:0.011682:0.004738:0.004738
N Engl J Med:@0.157791:0.321622:0.265993:0.321622:0.265993:0.307617:0.157791:0.307617:0.012657:0.004738:0.009168:0.010434:0.011511:0.003421:0.004738:0.008244:0.004738:0.015719:0.011118:0.011716
. 2007;356(22):2271.:@0.265976:0.321622:0.425474:0.321622:0.425474:0.307617:0.265976:0.307617:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
5. :@0.084242:0.335733:0.103194:0.335733:0.103194:0.321728:0.084242:0.321728:0.009476:0.004738:0.004738
 Motzer RJ,:@0.120589:0.335733:0.205791:0.335733:0.205791:0.321728:0.120589:0.321728:0.000000:0.015719:0.011203:0.005798:0.007269:0.011118:0.005148:0.005581:0.010382:0.008244:0.004738
 et al.:@0.205791:0.335733:0.253735:0.335733:0.253735:0.321728:0.205791:0.321728:0.005593:0.011118:0.005798:0.005593:0.011682:0.003421:0.004738
 Phase 3 trial of everolimus :@0.253735:0.335733:0.479870:0.335733:0.479870:0.321728:0.253735:0.321728:0.005593:0.010126:0.010434:0.011682:0.006636:0.011118:0.005593:0.009476:0.005593:0.005798:0.005148:0.003421:0.011682:0.003421:0.005593:0.011203:0.005371:0.005593:0.011118:0.009476:0.011118:0.005078:0.011203:0.003421:0.003421:0.016044:0.010399:0.006636:0.004738
for  metastatic  renal  cell  carcinoma:  final :@0.120589:0.349844:0.479888:0.349844:0.479888:0.335839:0.120589:0.335839:0.005371:0.011203:0.005148:0.004738:0.003816:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.004738:0.003825:0.005078:0.011118:0.010434:0.011682:0.003421:0.004738:0.003825:0.011067:0.011118:0.003421:0.003421:0.004738:0.003828:0.011067:0.011682:0.005029:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738:0.003819:0.004165:0.004165:0.010434:0.011682:0.003421:0.004738
results and analysis  of prognostic factors. :@0.120589:0.363956:0.479900:0.363956:0.479900:0.349950:0.120589:0.349950:0.005078:0.011118:0.006636:0.010399:0.003421:0.005798:0.006636:0.008467:0.011682:0.010434:0.011716:0.008467:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636:0.004738:0.003739:0.011203:0.005371:0.008467:0.011665:0.005080:0.011203:0.011511:0.010434:0.011203:0.006636:0.005798:0.003421:0.011058:0.008467:0.005371:0.011682:0.011067:0.005798:0.011203:0.005148:0.006636:0.004738:0.004738
Cancer.:@0.120589:0.378067:0.188682:0.378067:0.188682:0.364061:0.120589:0.364061:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738
 2010;116(18):4256.:@0.188665:0.378067:0.343425:0.378067:0.343425:0.364061:0.188665:0.364061:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
6. :@0.084242:0.392178:0.103194:0.392178:0.103194:0.378172:0.084242:0.378172:0.009476:0.004738:0.004738
 Rini  BI,:@0.120589:0.392178:0.174341:0.392178:0.174341:0.378172:0.120589:0.378172:0.000000:0.010382:0.003421:0.010434:0.003421:0.004738:0.002935:0.009818:0.003866:0.004738
  et  al.:@0.174341:0.392178:0.226433:0.392178:0.226433:0.378172:0.174341:0.378172:0.004738:0.002932:0.011118:0.005798:0.004738:0.002927:0.011682:0.003421:0.004738
  Bevacizumab plus interferon :@0.226433:0.392178:0.479895:0.392178:0.479895:0.378172:0.226433:0.378172:0.004738:0.002932:0.009818:0.011118:0.009476:0.011682:0.011067:0.003421:0.007269:0.010399:0.016044:0.011682:0.011665:0.007680:0.011665:0.003421:0.010399:0.006636:0.007680:0.003421:0.010434:0.005798:0.011118:0.005959:0.005371:0.011118:0.005077:0.011203:0.010434:0.004738
alfa compared with interferon alfa mono-:@0.120589:0.406289:0.475145:0.406289:0.475145:0.392284:0.120589:0.392284:0.011682:0.003421:0.005371:0.011682:0.006465:0.011067:0.011203:0.016044:0.011665:0.011682:0.005082:0.011118:0.011716:0.006465:0.014214:0.003421:0.005798:0.010434:0.006465:0.003421:0.010434:0.005798:0.011118:0.005959:0.005371:0.011118:0.005077:0.011203:0.010434:0.006457:0.011682:0.003421:0.005371:0.011682:0.006465:0.016044:0.011203:0.010434:0.011190:0.005679
therapy in patients with metastatic renal :@0.120589:0.420400:0.479865:0.420400:0.479865:0.406395:0.120589:0.406395:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.008894:0.003421:0.010434:0.008894:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.008894:0.014214:0.003421:0.005798:0.010434:0.008894:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.008894:0.005078:0.011118:0.010434:0.011682:0.003421:0.004738
cell carcinoma: CALGB 90206. :@0.120589:0.434511:0.385741:0.434511:0.385741:0.420506:0.120589:0.420506:0.011067:0.011118:0.003421:0.003421:0.007902:0.011067:0.011682:0.005029:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.004738:0.007902:0.013906:0.012657:0.007902:0.014915:0.009818:0.007902:0.009476:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738
J Clin On-:@0.388939:0.434511:0.475145:0.434511:0.475145:0.420506:0.388939:0.420506:0.008244:0.007902:0.013906:0.003421:0.003421:0.010434:0.007902:0.014864:0.010434:0.005679
col. :@0.120589:0.448622:0.155756:0.448622:0.155756:0.434617:0.120589:0.434617:0.011067:0.011203:0.003421:0.004738:0.004738
2008;26(33):5422.:@0.155756:0.448622:0.296302:0.448622:0.296302:0.434617:0.155756:0.434617:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
7. :@0.084242:0.462733:0.103194:0.462733:0.103194:0.448728:0.084242:0.448728:0.009476:0.004738:0.004738
 Motzer  RJ,:@0.120589:0.462733:0.208454:0.462733:0.208454:0.448728:0.120589:0.448728:0.000000:0.015719:0.011203:0.005798:0.007269:0.011118:0.005148:0.004738:0.003506:0.010382:0.008244:0.004738
 et al.:@0.208454:0.462733:0.261734:0.462733:0.261734:0.448728:0.208454:0.448728:0.008261:0.011118:0.005798:0.008261:0.011682:0.003421:0.004738
 Overall survival  and up-:@0.261734:0.462733:0.475159:0.462733:0.475159:0.448728:0.261734:0.448728:0.008261:0.014864:0.009476:0.011118:0.005148:0.011682:0.003421:0.003421:0.008261:0.006636:0.010399:0.005148:0.009476:0.003421:0.009476:0.011682:0.003421:0.004738:0.003537:0.011682:0.010434:0.011716:0.008261:0.010399:0.011665:0.005679
dated results for  sunitinib compared with :@0.120589:0.476844:0.479900:0.476844:0.479900:0.462839:0.120589:0.462839:0.011716:0.011682:0.005798:0.011118:0.011716:0.008535:0.005078:0.011118:0.006636:0.010399:0.003421:0.005798:0.006636:0.008535:0.005371:0.011203:0.005148:0.004738:0.003783:0.006636:0.010399:0.010434:0.003421:0.005798:0.003421:0.010434:0.003421:0.011665:0.008535:0.011067:0.011203:0.016044:0.011665:0.011682:0.005078:0.011118:0.011716:0.008535:0.014214:0.003421:0.005798:0.010434:0.004738
interferon  alfa in patients with  meta-:@0.120589:0.490956:0.475161:0.490956:0.475161:0.476950:0.120589:0.476950:0.003421:0.010434:0.005798:0.011118:0.005961:0.005371:0.011118:0.005075:0.011203:0.010434:0.004738:0.010832:0.011682:0.003421:0.005371:0.011682:0.015582:0.003421:0.010434:0.015582:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.015582:0.014214:0.003421:0.005798:0.010434:0.004738:0.010834:0.016044:0.011118:0.005798:0.011682:0.005679
static renal cell carcinoma. :@0.120589:0.505067:0.360818:0.505067:0.360818:0.491061:0.120589:0.491061:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.007988:0.005078:0.011118:0.010434:0.011682:0.003421:0.007988:0.011067:0.011118:0.003421:0.003421:0.007988:0.011067:0.011682:0.005029:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738
J  Clin Oncol.:@0.364036:0.505067:0.475154:0.505067:0.475154:0.491061:0.364036:0.491061:0.008244:0.004738:0.003241:0.013906:0.003421:0.003421:0.010434:0.007988:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 :@0.475154:0.505067:0.479892:0.505067:0.479892:0.491061:0.475154:0.491061:0.004738
2009;27(22):3584.:@0.120589:0.519178:0.261136:0.519178:0.261136:0.505172:0.120589:0.505172:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
8. :@0.084242:0.533289:0.103194:0.533289:0.103194:0.519284:0.084242:0.519284:0.009476:0.004738:0.004738
 Escudier  B,:@0.120589:0.533289:0.212395:0.533289:0.212395:0.519284:0.120589:0.519284:0.000000:0.009168:0.006636:0.011067:0.010399:0.011716:0.003421:0.011118:0.005148:0.004738:0.003838:0.009818:0.004738
 et al.:@0.212395:0.533289:0.266291:0.533289:0.266291:0.519284:0.212395:0.519284:0.008569:0.011118:0.005798:0.008569:0.011682:0.003421:0.004738
 Sorafenib for treatment :@0.266291:0.533289:0.479885:0.533289:0.479885:0.519284:0.266291:0.519284:0.008569:0.008518:0.011203:0.005148:0.011682:0.005371:0.011118:0.010434:0.003421:0.011665:0.008569:0.005371:0.011203:0.005148:0.008569:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738
of renal cell carcinoma: final efficacy and :@0.120589:0.547400:0.479888:0.547400:0.479888:0.533395:0.120589:0.533395:0.011203:0.005371:0.005891:0.005077:0.011118:0.010434:0.011682:0.003421:0.005896:0.011067:0.011118:0.003421:0.003421:0.005899:0.011067:0.011682:0.005029:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.004738:0.005891:0.004165:0.004165:0.010434:0.011682:0.003421:0.005894:0.011118:0.005371:0.004165:0.004165:0.011067:0.011682:0.011067:0.009168:0.005892:0.011682:0.010434:0.011716:0.004738
safety results of the phase III treatment ap-:@0.120589:0.561511:0.475156:0.561511:0.475156:0.547506:0.120589:0.547506:0.006636:0.011682:0.005371:0.011118:0.005798:0.009168:0.005251:0.005078:0.011118:0.006636:0.010399:0.003421:0.005798:0.006636:0.005251:0.011203:0.005371:0.005251:0.005798:0.010434:0.011118:0.005251:0.011665:0.010434:0.011682:0.006636:0.011118:0.005251:0.003866:0.003866:0.003866:0.005251:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.005251:0.011682:0.011665:0.005679
proaches in renal cancer global evalua-:@0.120589:0.575622:0.475125:0.575622:0.475125:0.561617:0.120589:0.561617:0.011665:0.005080:0.011203:0.011682:0.011067:0.010434:0.011118:0.006636:0.008638:0.003421:0.010434:0.008638:0.005077:0.011118:0.010434:0.011682:0.003421:0.008638:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.008638:0.011511:0.003421:0.011203:0.011665:0.011682:0.003421:0.008638:0.011118:0.009476:0.011682:0.003421:0.010399:0.011682:0.005679
tion trial. :@0.120589:0.589733:0.195130:0.589733:0.195130:0.575728:0.120589:0.575728:0.005798:0.003421:0.011203:0.010434:0.004738:0.005798:0.005148:0.003421:0.011682:0.003421:0.004738:0.004738
J Clin Oncol:@0.195113:0.589733:0.295002:0.589733:0.295002:0.575728:0.195113:0.575728:0.008244:0.004738:0.013906:0.003421:0.003421:0.010434:0.004738:0.014864:0.010434:0.011067:0.011203:0.003421
. 2009;27(20):3312.:@0.295002:0.589733:0.445025:0.589733:0.445025:0.575728:0.295002:0.575728:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
9. :@0.084242:0.603844:0.103194:0.603844:0.103194:0.589839:0.084242:0.589839:0.009476:0.004738:0.004738
 Rini BI,:@0.120589:0.603844:0.172550:0.603844:0.172550:0.589839:0.120589:0.589839:0.000000:0.010382:0.003421:0.010434:0.003421:0.005882:0.009818:0.003866:0.004738
 et al.:@0.172550:0.603844:0.221067:0.603844:0.221067:0.589839:0.172550:0.589839:0.005884:0.011118:0.005798:0.005875:0.011682:0.003421:0.004738
 Comparative effectiveness of :@0.221067:0.603844:0.479904:0.603844:0.479904:0.589839:0.221067:0.589839:0.005884:0.013906:0.011203:0.016044:0.011665:0.011682:0.005148:0.011682:0.005798:0.003421:0.009476:0.011118:0.005884:0.011118:0.005419:0.005371:0.011118:0.011067:0.005798:0.003421:0.009476:0.011118:0.010434:0.011118:0.006636:0.006636:0.005884:0.011203:0.005371:0.004738
axitinib:@0.120589:0.617956:0.178641:0.617956:0.178641:0.603950:0.120589:0.603950:0.011682:0.008210:0.003421:0.005798:0.003421:0.010434:0.003421:0.011665
 versus:@0.178641:0.617956:0.233238:0.617956:0.233238:0.603950:0.178641:0.603950:0.005183:0.009476:0.011118:0.005148:0.006636:0.010399:0.006636
 sorafenib in advanced renal :@0.233238:0.617956:0.479865:0.617956:0.479865:0.603950:0.233238:0.603950:0.005183:0.006636:0.011203:0.005148:0.011682:0.005371:0.011118:0.010434:0.003421:0.011665:0.005183:0.003421:0.010434:0.005183:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.005183:0.005078:0.011118:0.010434:0.011682:0.003421:0.004738
cell carcinoma (AXIS): a randomised phase :@0.120589:0.632067:0.479868:0.632067:0.479868:0.618061:0.120589:0.618061:0.011067:0.011118:0.003421:0.003421:0.003746:0.011067:0.011682:0.005030:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.003746:0.006312:0.012657:0.010417:0.003866:0.008518:0.006312:0.004738:0.003746:0.011682:0.003746:0.005148:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.006636:0.011118:0.011716:0.003746:0.011665:0.010434:0.011682:0.006636:0.011118:0.004738
3 trial. :@0.120589:0.646178:0.176281:0.646178:0.176281:0.632172:0.120589:0.632172:0.009476:0.007269:0.005798:0.005148:0.003421:0.011682:0.003421:0.004738:0.004738
Lancet.:@0.178812:0.646178:0.241551:0.646178:0.241551:0.632172:0.178812:0.632172:0.007902:0.011682:0.010434:0.011067:0.011118:0.005798:0.004738
 2011 Dec;378(9807):1931-9. :@0.241534:0.646178:0.479866:0.646178:0.479866:0.632172:0.241534:0.632172:0.007269:0.009476:0.009476:0.009476:0.009476:0.007269:0.012726:0.011118:0.011067:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009493:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.004738:0.004738
(Epub 2011 Nov 4).:@0.120589:0.660289:0.275777:0.660289:0.275777:0.646284:0.120589:0.646284:0.006312:0.009168:0.011665:0.010399:0.011665:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.012657:0.011203:0.009476:0.004738:0.009476:0.006312:0.004738
10.   Sternberg  CN,:@0.084242:0.674400:0.246441:0.674400:0.246441:0.660395:0.084242:0.660395:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.008518:0.005798:0.011118:0.005501:0.010434:0.011665:0.011118:0.005159:0.011511:0.004738:0.008992:0.013906:0.012657:0.004738
 et al.:@0.246441:0.674400:0.310668:0.674400:0.310668:0.660395:0.246441:0.660395:0.013735:0.011118:0.005798:0.013735:0.011682:0.003421:0.004738
 Pazopanib in lo-:@0.310668:0.674400:0.475178:0.674400:0.475178:0.660395:0.310668:0.660395:0.013735:0.010126:0.011682:0.007269:0.011203:0.011665:0.011682:0.010434:0.003421:0.011665:0.013735:0.003421:0.010434:0.013735:0.003421:0.011203:0.005679
cally advanced  or  metastatic  renal  cell :@0.120589:0.688511:0.479882:0.688511:0.479882:0.674506:0.120589:0.674506:0.011067:0.011682:0.003421:0.003421:0.009168:0.010160:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.004738:0.005410:0.011203:0.005148:0.004738:0.005403:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.004738:0.005412:0.005078:0.011118:0.010434:0.011682:0.003421:0.004738:0.005412:0.011067:0.011118:0.003421:0.003421:0.004738
carcinoma: results of a randomised phase :@0.559983:0.094645:0.919276:0.094645:0.919276:0.080640:0.559983:0.080640:0.011067:0.011682:0.005029:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.004738:0.006038:0.005078:0.011118:0.006636:0.010399:0.003421:0.005798:0.006636:0.006038:0.011203:0.005371:0.006038:0.011682:0.006038:0.005148:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.006636:0.011118:0.011716:0.006038:0.011665:0.010434:0.011682:0.006636:0.011118:0.004738
III trial. :@0.559983:0.108780:0.615264:0.108780:0.615264:0.094774:0.559983:0.094774:0.003866:0.003866:0.003866:0.004738:0.005798:0.005148:0.003421:0.011682:0.003421:0.004738:0.004738
J Clin Oncol:@0.615264:0.108780:0.715154:0.108780:0.715154:0.094774:0.615264:0.094774:0.008244:0.004738:0.013906:0.003421:0.003421:0.010434:0.004738:0.014864:0.010434:0.011067:0.011203:0.003421
. 2010;28(6):1061.:@0.715154:0.108780:0.855700:0.108780:0.855700:0.094774:0.715154:0.094774:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
11.    Motzer RJ, :@0.523636:0.122914:0.650706:0.122914:0.650706:0.108909:0.523636:0.108909:0.009476:0.009476:0.004738:0.004738:0.004738:0.003180:0.000000:0.015719:0.011203:0.005798:0.007269:0.011118:0.005148:0.006366:0.010382:0.008244:0.004738:0.004738
et al:@0.652347:0.122914:0.690746:0.122914:0.690746:0.108909:0.652347:0.108909:0.011118:0.005798:0.006380:0.011682:0.003421
. Nivolumab versus everoli-:@0.690746:0.122914:0.914521:0.122914:0.914521:0.108909:0.690746:0.108909:0.004738:0.006380:0.012657:0.003421:0.009476:0.011203:0.003421:0.010399:0.016044:0.011682:0.011665:0.006380:0.009476:0.011118:0.005148:0.006636:0.010399:0.006636:0.006380:0.011118:0.009476:0.011118:0.005078:0.011203:0.003421:0.003421:0.005679
mus in advanced renal-cell carcinoma. :@0.559983:0.137049:0.899965:0.137049:0.899965:0.123044:0.559983:0.123044:0.016044:0.010399:0.006636:0.006654:0.003421:0.010434:0.006654:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.006654:0.005078:0.011118:0.010434:0.011682:0.003421:0.005679:0.011067:0.011118:0.003421:0.003421:0.006654:0.011067:0.011682:0.005029:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738
N :@0.901880:0.137049:0.919276:0.137049:0.919276:0.123044:0.901880:0.123044:0.012657:0.004738
Engl J Med.:@0.559983:0.151183:0.661104:0.151183:0.661104:0.137178:0.559983:0.137178:0.009168:0.010434:0.011511:0.003421:0.007526:0.008244:0.007526:0.015719:0.011118:0.011716:0.004738
 2015;373(19):1803. Epub 2015 :@0.661104:0.151183:0.919284:0.151183:0.919284:0.137178:0.661104:0.137178:0.007526:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009517:0.009476:0.004738:0.007526:0.009168:0.011665:0.010399:0.011665:0.007526:0.009476:0.009476:0.009476:0.009476:0.004738
Sep 25.:@0.559983:0.165318:0.619711:0.165318:0.619711:0.151313:0.559983:0.151313:0.008518:0.011118:0.011665:0.004738:0.009476:0.009476:0.004738
12.   European Association of Urology. Updated :@0.523636:0.179453:0.919286:0.179453:0.919286:0.165447:0.523636:0.165447:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.009168:0.010399:0.005078:0.011203:0.011665:0.011118:0.011682:0.010434:0.005166:0.012657:0.006636:0.006636:0.011203:0.011067:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.005166:0.011203:0.005371:0.005166:0.011203:0.005073:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.005166:0.011203:0.011665:0.011716:0.011682:0.005798:0.011118:0.011716:0.004738
guidelines recommendations for the treat-:@0.559983:0.193587:0.914550:0.193587:0.914550:0.179582:0.559983:0.179582:0.011511:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.006636:0.006038:0.005078:0.011118:0.011067:0.011203:0.016044:0.016044:0.011118:0.010434:0.011716:0.011682:0.005798:0.003421:0.011203:0.010434:0.006636:0.006038:0.005371:0.011203:0.005148:0.006038:0.005798:0.010434:0.011118:0.006038:0.005798:0.005075:0.011118:0.011682:0.005798:0.005679
ment of first-line metastatic clear cell renal :@0.559983:0.207722:0.919282:0.207722:0.919282:0.193717:0.559983:0.193717:0.016044:0.011118:0.010434:0.005798:0.005390:0.011203:0.005371:0.005391:0.004165:0.004165:0.005148:0.006636:0.005798:0.005679:0.003421:0.003421:0.010434:0.011118:0.005395:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.005396:0.011067:0.003421:0.011118:0.011682:0.005148:0.005395:0.011067:0.011118:0.003421:0.003421:0.005402:0.005078:0.011118:0.010434:0.011682:0.003421:0.004738
cancer. :@0.559983:0.221857:0.628715:0.221857:0.628715:0.207851:0.559983:0.207851:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004738:0.004738
Eur Urol.:@0.628715:0.221857:0.693883:0.221857:0.693883:0.207851:0.628715:0.207851:0.009168:0.010399:0.005148:0.004738:0.011203:0.005148:0.011203:0.003421:0.004738
 2017;73(3):311-315:@0.693859:0.221857:0.849560:0.221857:0.849560:0.207851:0.693859:0.207851:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476
13.   Mak RH, :@0.523636:0.235991:0.633708:0.235991:0.633708:0.221986:0.523636:0.221986:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.015719:0.011682:0.008586:0.006197:0.010382:0.011682:0.004738:0.004738
et al:@0.635157:0.235991:0.673368:0.235991:0.673368:0.221986:0.635157:0.221986:0.011118:0.005798:0.006192:0.011682:0.003421
. Long-term outcomes in pa-:@0.673368:0.235991:0.914519:0.235991:0.914519:0.221986:0.673368:0.221986:0.004738:0.006192:0.007902:0.011203:0.010434:0.011511:0.005679:0.005798:0.011118:0.005607:0.016044:0.006192:0.011203:0.010399:0.005798:0.011067:0.011203:0.016044:0.011118:0.006636:0.006192:0.003421:0.010434:0.006192:0.011665:0.011682:0.005679
tients with muscle-invasive bladder cancer :@0.559983:0.250126:0.919277:0.250126:0.919277:0.236121:0.559983:0.236121:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.005114:0.014214:0.003421:0.005798:0.010434:0.005114:0.016044:0.010399:0.006636:0.011067:0.003421:0.011118:0.005679:0.003421:0.010434:0.009476:0.011682:0.006636:0.003421:0.009476:0.011118:0.005131:0.011665:0.003421:0.011682:0.011716:0.011716:0.011118:0.005148:0.005114:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738
after  selective bladder-preserving com-:@0.559983:0.264261:0.914551:0.264261:0.914551:0.250255:0.559983:0.250255:0.011682:0.005371:0.005798:0.011118:0.005148:0.004738:0.008764:0.006636:0.011118:0.003421:0.011118:0.011067:0.005798:0.003421:0.009476:0.011118:0.013512:0.011665:0.003421:0.011682:0.011716:0.011716:0.011118:0.005148:0.005679:0.011665:0.005085:0.011118:0.006636:0.011118:0.005148:0.009476:0.003421:0.010434:0.011511:0.013512:0.011067:0.011203:0.016044:0.005679
bined-modality therapy: a pooled analysis :@0.559983:0.278395:0.919257:0.278395:0.919257:0.264390:0.559983:0.264390:0.011665:0.003421:0.010434:0.011118:0.011716:0.005679:0.016044:0.011203:0.011716:0.011682:0.003421:0.003421:0.005798:0.009168:0.005812:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.005798:0.011682:0.005798:0.011665:0.011203:0.011203:0.003421:0.011118:0.011716:0.005798:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636:0.004738
of radiation-therapy group protocols 8802, :@0.559983:0.292530:0.919281:0.292530:0.919281:0.278525:0.559983:0.278525:0.011203:0.005371:0.005752:0.005148:0.011682:0.011716:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.005679:0.005798:0.010434:0.011118:0.005148:0.011672:0.011665:0.009168:0.005764:0.011511:0.005077:0.011203:0.010399:0.011665:0.005752:0.011665:0.005080:0.011203:0.005798:0.011193:0.011067:0.011203:0.003421:0.006636:0.005764:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738
8903, 9506, 9706, 9906 and 0233. :@0.559983:0.306664:0.833186:0.306664:0.833186:0.292659:0.559983:0.292659:0.009476:0.009476:0.009476:0.009476:0.004738:0.005234:0.009476:0.009476:0.009486:0.009476:0.004738:0.005225:0.009476:0.009476:0.009476:0.009476:0.004750:0.005224:0.009476:0.009476:0.009476:0.009476:0.005234:0.011682:0.010434:0.011716:0.005225:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738
J Clin On-:@0.833682:0.306664:0.914539:0.306664:0.914539:0.292659:0.833682:0.292659:0.008244:0.005222:0.013906:0.003421:0.003421:0.010434:0.005234:0.014864:0.010434:0.005679
col:@0.559983:0.320799:0.585674:0.320799:0.585674:0.306794:0.559983:0.306794:0.011067:0.011203:0.003421
. 2014;32(34):3801.:@0.585674:0.320799:0.735696:0.320799:0.735696:0.306794:0.585674:0.306794:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
14.   Von der Maase H,:@0.523636:0.334934:0.710332:0.334934:0.710332:0.320928:0.523636:0.320928:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010281:0.011203:0.010434:0.005730:0.011716:0.011118:0.005148:0.005730:0.015719:0.011682:0.011682:0.006636:0.011118:0.005730:0.011682:0.004738
 et al.:@0.710332:0.334934:0.758549:0.334934:0.758549:0.320928:0.710332:0.320928:0.005730:0.011118:0.005798:0.005730:0.011682:0.003421:0.004738
 Gemcitabine and :@0.758549:0.334934:0.919262:0.334934:0.919262:0.320928:0.758549:0.320928:0.005730:0.014915:0.011118:0.016044:0.011067:0.003421:0.005798:0.011682:0.011665:0.003421:0.010434:0.011118:0.005730:0.011682:0.010434:0.011716:0.004738
cisplatin:@0.559983:0.349068:0.627528:0.349068:0.627528:0.335063:0.559983:0.335063:0.011067:0.003421:0.006636:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434
  versus:@0.627545:0.349068:0.686032:0.349068:0.686032:0.335063:0.627545:0.335063:0.004738:0.004334:0.009476:0.011118:0.005148:0.006636:0.010399:0.006636
  methotrexate,  vinblastine, :@0.686032:0.349068:0.919277:0.349068:0.919277:0.335063:0.686032:0.335063:0.004738:0.004334:0.016044:0.011118:0.005798:0.010434:0.011203:0.005798:0.005066:0.011118:0.008210:0.011682:0.005798:0.011118:0.004738:0.004738:0.004327:0.009476:0.003421:0.010434:0.011665:0.003421:0.011682:0.006636:0.005798:0.003421:0.010434:0.011118:0.004738:0.004738
doxorubicin,  and cisplatin in advanced :@0.559983:0.363203:0.919281:0.363203:0.919281:0.349198:0.559983:0.349198:0.011716:0.011203:0.008210:0.011203:0.005148:0.010399:0.011665:0.003421:0.011067:0.003421:0.010434:0.004738:0.004738:0.007204:0.011682:0.010434:0.011716:0.011956:0.011067:0.003421:0.006636:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.011956:0.003421:0.010434:0.011956:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.004738
or  metastatic bladder cancer:  results of :@0.559983:0.377338:0.919296:0.377338:0.919296:0.363332:0.559983:0.363332:0.011203:0.005148:0.004738:0.005614:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.010365:0.011665:0.003421:0.011682:0.011716:0.011716:0.011118:0.005148:0.010365:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004738:0.005612:0.005077:0.011118:0.006636:0.010399:0.003421:0.005798:0.006636:0.010365:0.011203:0.005371:0.004738
a large,  randomised, multinational, multi-:@0.559983:0.391472:0.914556:0.391472:0.914556:0.377467:0.559983:0.377467:0.011682:0.008689:0.003421:0.011682:0.005160:0.011511:0.011118:0.004738:0.004738:0.003939:0.005148:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.006636:0.011118:0.011716:0.004738:0.008689:0.016044:0.010399:0.003421:0.005798:0.003421:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.004738:0.008689:0.016044:0.010399:0.003421:0.005798:0.003421:0.005679
center, phase III study. :@0.559983:0.405607:0.754294:0.405607:0.754294:0.391602:0.559983:0.391602:0.011067:0.011118:0.010434:0.005798:0.011118:0.003340:0.004738:0.006790:0.011665:0.010434:0.011682:0.006636:0.011118:0.006790:0.003866:0.003866:0.003866:0.006790:0.006636:0.005798:0.010399:0.011716:0.009168:0.004738:0.004738
J Clin Oncol:@0.756346:0.405607:0.860341:0.405607:0.860341:0.391602:0.756346:0.391602:0.008244:0.006790:0.013906:0.003421:0.003421:0.010434:0.006790:0.014864:0.010434:0.011067:0.011203:0.003421
. 2000; :@0.860341:0.405607:0.919248:0.405607:0.919248:0.391602:0.860341:0.391602:0.004738:0.006790:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738
18(17):3068.:@0.559983:0.419741:0.657888:0.419741:0.657888:0.405736:0.559983:0.405736:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
15.   De Santis M,:@0.523636:0.433876:0.666748:0.433876:0.666748:0.419871:0.523636:0.419871:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.012726:0.011118:0.007988:0.008518:0.011682:0.010434:0.005798:0.003421:0.006636:0.007988:0.015719:0.004738
 et al.:@0.666748:0.433876:0.719481:0.433876:0.719481:0.419871:0.666748:0.419871:0.007988:0.011118:0.005798:0.007988:0.011682:0.003421:0.004738
 Randomised phase II/:@0.719481:0.433876:0.914539:0.433876:0.914539:0.419871:0.719481:0.419871:0.007988:0.010382:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.006636:0.011118:0.011716:0.007988:0.011665:0.010434:0.011682:0.006636:0.011118:0.007988:0.003866:0.003866:0.007475
III trial assessing gemcitabine/carboplatin :@0.559983:0.448011:0.919277:0.448011:0.919277:0.434005:0.559983:0.434005:0.003866:0.003866:0.003866:0.008946:0.005798:0.005148:0.003421:0.011682:0.003421:0.008946:0.011682:0.006636:0.006636:0.011118:0.006636:0.006636:0.003421:0.010434:0.011511:0.008946:0.011511:0.011118:0.016044:0.011067:0.003421:0.005798:0.011682:0.011665:0.003421:0.010434:0.011118:0.007475:0.011067:0.011682:0.005148:0.011665:0.011203:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.004738
and methotrexate/carboplatin/vinblastine :@0.559983:0.462145:0.919281:0.462145:0.919281:0.448140:0.559983:0.448140:0.011682:0.010434:0.011716:0.007697:0.016044:0.011118:0.005798:0.010434:0.011203:0.005798:0.005066:0.011118:0.008210:0.011682:0.005798:0.011118:0.007475:0.011067:0.011682:0.005148:0.011665:0.011203:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.007475:0.009476:0.003421:0.010434:0.011665:0.003421:0.011682:0.006636:0.005798:0.003421:0.010434:0.011118:0.004738
in  patients  with  advanced urothelial can-:@0.559983:0.476280:0.914555:0.476280:0.914555:0.462275:0.559983:0.462275:0.003421:0.010434:0.004738:0.002574:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004738:0.002571:0.014214:0.003421:0.005798:0.010434:0.004738:0.002572:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.007321:0.010399:0.005075:0.011203:0.005798:0.010434:0.011118:0.003421:0.003421:0.011682:0.003421:0.007321:0.011067:0.011682:0.010434:0.005679
cer who are unfit for cisplatin-based chem-:@0.559983:0.490415:0.914550:0.490415:0.914550:0.476409:0.559983:0.476409:0.011067:0.011118:0.005148:0.004403:0.014214:0.010434:0.011203:0.004403:0.011682:0.005078:0.011118:0.004406:0.010399:0.010434:0.004165:0.004165:0.005790:0.004408:0.005371:0.011203:0.005148:0.004399:0.011067:0.003421:0.006636:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.005679:0.011665:0.011682:0.006636:0.011118:0.011716:0.004428:0.011067:0.010434:0.011118:0.016044:0.005679
otherapy: EORTC study 30986. :@0.559983:0.504549:0.810666:0.504549:0.810666:0.490544:0.559983:0.490544:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004481:0.009168:0.014864:0.010487:0.007286:0.013906:0.004481:0.006636:0.005798:0.010399:0.011716:0.009168:0.004481:0.009476:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738
J Clin Oncol:@0.810425:0.504549:0.909801:0.504549:0.909801:0.490544:0.810425:0.490544:0.008244:0.004481:0.013906:0.003421:0.003421:0.010434:0.004481:0.014864:0.010434:0.011067:0.011203:0.003421
. :@0.909801:0.504549:0.919277:0.504549:0.919277:0.490544:0.909801:0.490544:0.004738:0.004738
2012;30(2):191.:@0.559983:0.518684:0.681578:0.518684:0.681578:0.504679:0.559983:0.504679:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.004738
16.   Calabrò  F,:@0.523636:0.532818:0.647417:0.532818:0.647417:0.518813:0.523636:0.518813:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.013906:0.011682:0.003421:0.011682:0.011665:0.005148:0.011203:0.004738:0.003045:0.006205:0.004738
 et al.:@0.647417:0.532818:0.699739:0.532818:0.699739:0.518813:0.647417:0.518813:0.007782:0.011118:0.005798:0.007782:0.011682:0.003421:0.004738
 Gemcitabine and pacli-:@0.699739:0.532818:0.914539:0.532818:0.914539:0.518813:0.699739:0.518813:0.007782:0.014915:0.011118:0.016044:0.011067:0.003421:0.005798:0.011682:0.011665:0.003421:0.010434:0.011118:0.007782:0.011682:0.010434:0.011716:0.007782:0.011665:0.011682:0.011067:0.003421:0.003424:0.005679
taxel every 2 weeks in patients with previ-:@0.559983:0.546953:0.914558:0.546953:0.914558:0.532948:0.559983:0.532948:0.005798:0.011682:0.008210:0.011118:0.003421:0.006636:0.011118:0.009476:0.011118:0.005148:0.009168:0.006636:0.009476:0.006636:0.014214:0.011118:0.011118:0.008586:0.006636:0.006636:0.003421:0.010434:0.006636:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.006636:0.014214:0.003421:0.005798:0.010434:0.006636:0.011665:0.005082:0.011118:0.009476:0.003421:0.005679
ously untreated urothelial carcinoma. :@0.559983:0.561088:0.873451:0.561088:0.873451:0.547082:0.559983:0.547082:0.011203:0.010399:0.006636:0.003421:0.009168:0.004139:0.010399:0.010434:0.005798:0.005077:0.011118:0.011682:0.005798:0.011118:0.011716:0.004139:0.010399:0.005078:0.011203:0.005798:0.010434:0.011118:0.003421:0.003421:0.011682:0.003421:0.004139:0.011067:0.011682:0.005030:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738
Can-:@0.872853:0.561088:0.914553:0.561088:0.914553:0.547082:0.872853:0.547082:0.013906:0.011682:0.010434:0.005679
cer:@0.559983:0.575222:0.587316:0.575222:0.587316:0.561217:0.559983:0.561217:0.011067:0.011118:0.005148
. 2009;115(12):2652.:@0.587316:0.575222:0.746814:0.575222:0.746814:0.561217:0.587316:0.561217:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
17.   Bellmunt J, de Wit R,  Vaughn  DJ, :@0.523636:0.589357:0.862470:0.589357:0.862470:0.575352:0.523636:0.575352:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.009818:0.011118:0.003421:0.003421:0.016044:0.010399:0.010434:0.005798:0.010040:0.008244:0.004738:0.010040:0.011716:0.011118:0.010040:0.016519:0.003421:0.005798:0.010040:0.010382:0.004738:0.004738:0.005294:0.010232:0.011682:0.010399:0.011511:0.010434:0.010434:0.004738:0.005290:0.012726:0.008244:0.004738:0.004738
et  al:@0.867773:0.589357:0.909824:0.589357:0.909824:0.575352:0.867773:0.575352:0.011118:0.005798:0.004738:0.005294:0.011682:0.003421
. :@0.909824:0.589357:0.919299:0.589357:0.919299:0.575352:0.909824:0.575352:0.004738:0.004738
Pembrolizumab as second-line therapy for :@0.559983:0.603492:0.919306:0.603492:0.919306:0.589486:0.559983:0.589486:0.010126:0.011118:0.016044:0.011665:0.005075:0.011203:0.003421:0.003421:0.007269:0.010399:0.016044:0.011682:0.011665:0.006038:0.011682:0.006636:0.006038:0.006636:0.011118:0.011067:0.011203:0.010434:0.011716:0.005679:0.003421:0.003421:0.010434:0.011118:0.006038:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.006038:0.005371:0.011203:0.005148:0.004738
advanced urothelial  carcinoma. :@0.559983:0.617626:0.841112:0.617626:0.841112:0.603621:0.559983:0.603621:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.007577:0.010399:0.005077:0.011203:0.005798:0.010425:0.011118:0.003421:0.003421:0.011682:0.003421:0.004738:0.002851:0.011067:0.011682:0.005030:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738
N Engl J :@0.843951:0.617626:0.919279:0.617626:0.919279:0.603621:0.843951:0.603621:0.012657:0.007577:0.009168:0.010434:0.011511:0.003421:0.007577:0.008244:0.004738
Med.:@0.559983:0.631761:0.603274:0.631761:0.603274:0.617756:0.559983:0.617756:0.015719:0.011118:0.011716:0.004738
 2017; 376:1015-1026.:@0.603274:0.631761:0.774780:0.631761:0.774780:0.617756:0.603274:0.617756:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
Acknowledgement: Dr SJ Fourie, clinical and :@0.523636:0.660042:0.897965:0.660042:0.897965:0.646037:0.523636:0.646037:0.012657:0.011067:0.008586:0.010434:0.011203:0.014214:0.003421:0.011118:0.011716:0.011511:0.011118:0.016044:0.011118:0.010434:0.005798:0.004738:0.004738:0.012726:0.005148:0.004738:0.008518:0.008244:0.004738:0.008296:0.011203:0.010399:0.005148:0.003421:0.011118:0.004738:0.004738:0.011067:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.004738:0.011682:0.010434:0.011716:0.004738
radiation oncologist in private practice, Pre-:@0.523636:0.674177:0.887573:0.674177:0.887573:0.660171:0.523636:0.660171:0.005148:0.011682:0.011716:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.011203:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.003421:0.006636:0.005798:0.004738:0.003421:0.010434:0.004738:0.011665:0.005148:0.003421:0.009476:0.011682:0.005798:0.011118:0.004738:0.011665:0.005148:0.011682:0.011067:0.005798:0.003421:0.011067:0.011118:0.004738:0.004738:0.010126:0.005053:0.011118:0.005679
toria:@0.523636:0.688311:0.560890:0.688311:0.560890:0.674306:0.523636:0.674306:0.005798:0.011203:0.005148:0.003421:0.011682